Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Advanced Malignant Pheochromocytoma or Paraganglioma
NCT01340794Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pazopanib in pheochromocytoma, Paraganglioma (PGL), sponsored by National Cancer Institute. Started May 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT01340794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340794.